Viking Therapeutics VKTX Non-Cash Lease Expense
Non-Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's non-cash lease expense?
- Viking Therapeutics (VKTX) reported non-cash lease expense of $85K in Q1 2026.
- How has Viking Therapeutics's non-cash lease expense changed year-over-year?
- Viking Therapeutics's non-cash lease expense decreased by 23.4% year-over-year, from $111K to $85K.
- What is the long-term trend for Viking Therapeutics's non-cash lease expense?
- Over 3 years (2022 to 2025), Viking Therapeutics's non-cash lease expense has grown at a 14.0% compound annual growth rate (CAGR), from $291K to $431K.
- What does non-cash lease expense mean?
- Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.